MA38135A2 - Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium - Google Patents

Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium

Info

Publication number
MA38135A2
MA38135A2 MA38135A MA38135A MA38135A2 MA 38135 A2 MA38135 A2 MA 38135A2 MA 38135 A MA38135 A MA 38135A MA 38135 A MA38135 A MA 38135A MA 38135 A2 MA38135 A2 MA 38135A2
Authority
MA
Morocco
Prior art keywords
calcium
potassium channel
channel inhibitors
activated potassium
oxazolidinone derivatives
Prior art date
Application number
MA38135A
Other languages
English (en)
Other versions
MA38135B1 (fr
Inventor
Luke Green
Haiyan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38135A2 publication Critical patent/MA38135A2/fr
Publication of MA38135B1 publication Critical patent/MA38135B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention porte sur des composés représentés par la formule générale i, dans laquelle n, r1, r2a, r2b, r3a et r3b sont tels que définis dans la description, sur des compositions comprenant les composés et sur des procédés d'utilisation des composés.
MA38135A 2012-10-29 2013-10-25 Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium MA38135B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12190319 2012-10-29
PCT/EP2013/072361 WO2014067861A1 (fr) 2012-10-29 2013-10-25 Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium

Publications (2)

Publication Number Publication Date
MA38135A2 true MA38135A2 (fr) 2016-11-30
MA38135B1 MA38135B1 (fr) 2018-11-30

Family

ID=47143594

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38135A MA38135B1 (fr) 2012-10-29 2013-10-25 Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium

Country Status (23)

Country Link
US (1) US9611232B2 (fr)
EP (1) EP2912034B1 (fr)
JP (1) JP6216385B2 (fr)
KR (1) KR20150075091A (fr)
CN (1) CN104781256B (fr)
AR (1) AR093168A1 (fr)
AU (1) AU2013339607A1 (fr)
BR (1) BR112015003996A2 (fr)
CA (1) CA2879249A1 (fr)
CL (1) CL2015000906A1 (fr)
CO (1) CO7170170A2 (fr)
CR (1) CR20150159A (fr)
EA (1) EA026161B1 (fr)
IL (1) IL237331A0 (fr)
IN (1) IN2015DN00961A (fr)
MA (1) MA38135B1 (fr)
MX (1) MX2015002399A (fr)
PE (1) PE20150775A1 (fr)
PH (1) PH12015500292A1 (fr)
SG (1) SG11201500585XA (fr)
TW (1) TW201422596A (fr)
UA (1) UA114649C2 (fr)
WO (1) WO2014067861A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102047502B1 (ko) * 2016-06-20 2019-11-22 셀라이온바이오메드 주식회사 포타슘 채널 단백질을 이용한 암 진단용 조성물
KR102865950B1 (ko) 2019-03-22 2025-09-30 사니오나 에이/에스 신규의 칼륨 채널 억제제
EP4217065A1 (fr) * 2020-09-22 2023-08-02 Saniona A/S Nouveaux inhibiteurs du canal potassique

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2538424C2 (de) * 1975-08-29 1983-01-05 Nordmark-Werke Gmbh, 2000 Hamburg 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat
DE3687870T2 (de) * 1985-09-09 1993-08-19 Otsuka Pharma Co Ltd 2-oxa-isocephemverbindungen, sie enthaltende zusammensetzungen und verfahren zu deren herstellung.
CA2095429A1 (fr) * 1990-11-06 1992-05-07 Paul E. Bender Composes d'imodazolidinone
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
WO1997031892A1 (fr) * 1996-03-01 1997-09-04 Sankyo Company, Limited Derives d'acide hydroxamique
AU760250B2 (en) * 1998-12-04 2003-05-08 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
EP1818326A1 (fr) * 2000-01-20 2007-08-15 Eisai R&D Management Co., Ltd. Hétérocycles azotés et compositions pharmaceutiques les contenant
JP3966693B2 (ja) * 2000-01-20 2007-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 含窒素環化合物およびそれらを含んでなる医薬組成物
CA2429308C (fr) * 2000-11-22 2010-09-21 Bayer Aktiengesellschaft Nouveaux derives de pyrazolopyridine substitues par lactame
CA2575003C (fr) 2004-07-29 2010-02-16 Merck & Co., Inc. Inhibiteurs de canal a potassium
DE102004060229A1 (de) * 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
US7378530B2 (en) * 2005-02-22 2008-05-27 Nereus Pharmaceuticals, Inc. Anti-cancer and anti-microbial 5-membered heterocyclic compounds
US20100056637A1 (en) 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
WO2007109098A2 (fr) * 2006-03-16 2007-09-27 Azevan Pharmaceuticals, Inc. ACIDES β-LACTAMYL ALCANEDIOÏQUES HYDROXY OU CÉTO-SUBSTITUÉS
AR074558A1 (es) * 2008-12-12 2011-01-26 Solvay Pharm Bv Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3
WO2010123997A1 (fr) * 2009-04-22 2010-10-28 Achaogen, Inc. Antibiotiques bêta-lactames carbacéphèmes

Also Published As

Publication number Publication date
JP6216385B2 (ja) 2017-10-18
AR093168A1 (es) 2015-05-20
PE20150775A1 (es) 2015-05-21
US9611232B2 (en) 2017-04-04
IN2015DN00961A (fr) 2015-06-12
AU2013339607A1 (en) 2015-02-05
JP2015535231A (ja) 2015-12-10
MA38135B1 (fr) 2018-11-30
CR20150159A (es) 2015-04-30
EP2912034B1 (fr) 2017-05-31
WO2014067861A1 (fr) 2014-05-08
CN104781256A (zh) 2015-07-15
CA2879249A1 (fr) 2014-05-08
BR112015003996A2 (pt) 2017-07-04
EA201590729A1 (ru) 2015-07-30
CL2015000906A1 (es) 2015-09-11
CN104781256B (zh) 2017-09-29
UA114649C2 (uk) 2017-07-10
US20150246894A1 (en) 2015-09-03
KR20150075091A (ko) 2015-07-02
TW201422596A (zh) 2014-06-16
SG11201500585XA (en) 2015-04-29
CO7170170A2 (es) 2015-01-28
HK1207632A1 (en) 2016-02-05
IL237331A0 (en) 2015-04-30
EP2912034A1 (fr) 2015-09-02
MX2015002399A (es) 2015-06-10
PH12015500292A1 (en) 2015-04-20
EA026161B1 (ru) 2017-03-31

Similar Documents

Publication Publication Date Title
MA37756A1 (fr) Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
ES2571489T3 (es) Producto cosmético sólido para labios
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
UY33750A (es) ?Compuestos insecticidas aromáticos derivados de bisamida, procesos e intermediarios para prepararlos y composiciones que los usan.?
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP2694489A4 (fr) Composés de dioxyde de thiadiazine condensés avec des dérivés oxacycliques en c5-c6 comme inhibiteurs de bace, compositions, et utilisation use
DOP2013000063A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
MX343829B (es) N-ciclilamidas como nematicidas.
MA33939B1 (fr) 5-alcynyl-pyrimidines
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
EP2731429A4 (fr) Composés, procédés de préparation et procédés d'utilisation
MA34652B1 (fr) Hétéroaryles et utilisations de ceux-ci
MY169267A (en) New aryl-quinoline derivatives
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
EP2400968A4 (fr) Composition, synthèses et procédés d'utilisation des dérivés d'arylpipérazine
UY33276A (es) Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y métodos de uso
UA106880C2 (uk) Нові гербіциди
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators
WO2013081778A3 (fr) Composés nitrones et leur utilisation dans le soin personnel
CL2013003068A1 (es) Compuestos derivados de 2-(etinil-piridin-2-il)-pirazolidin-3-ona, 2-(etinil-pirimidin-2-il)-pirazolidin-3-ona o 2-(etinil-piridazin-3-il)-pirazolidin-3-ona; moduladores alostericos positivos de mglur5; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar la esquizofrenia o enfermedades cognitivas.
MA32717B1 (fr) Sels de n-[6-cis- (2.6-dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)- [1.1'-biphenyl]-3-carboxamide
EP2914580A4 (fr) Dérivés de thioaryle à titre d'agonistes de gpr120